Benzinga | Jun 22, 2021 10:20AM EDT

Biocept Stock Moves Higher On Collaboration With Quest Diagnostics For Liquid Biopsy Testing For Lung Cancer Patients

* Biocept Inc (NASDAQ:BIOC) has collaborated with Quest Diagnostics Inc (NYSE:DGX) to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid biopsy targeted lung cancer panel.

* The Biocept Target Selector NGS-based liquid biopsy assay is a less invasive, lab-developed test used for genomic profiling in patients with advanced non-small-cell lung cancer to help qualify them for advanced targeted therapies and monitor the effectiveness of treatment.

* The two parties expect the service to be available to Quest Diagnostics' providers and patients in the fourth quarter of 2021.

* Price Action: BIOC shares are up 4.52% at $4.39 during the market session on the last check Tuesday.